Health and Fitness Health and Fitness
Wed, December 14, 2011
[ Wed, Dec 14th 2011 ] - Market Wire
Cannabis Science Negotiates Commercialization Dea .. rand Formulations Immediately into the California
[ Wed, Dec 14th 2011 ] - Market Wire
Glancy Binkow & Goldberg LLP Announces Investigation of Synovis Life Technologies, Inc.
[ Wed, Dec 14th 2011 ] - Market Wire
ViroPharma Announces Approval of Modernized Label .. Vancocin (vancomycin hydrochloride, USP) Capsules
[ Wed, Dec 14th 2011 ] - Market Wire
Positron's Attrius Receives Health Canada Approval
[ Wed, Dec 14th 2011 ] - Market Wire
AIM Honored for Innovative Program That Helps Consumers Make Better Choices About Their Care
[ Wed, Dec 14th 2011 ] - Market Wire
Vooraanstaande samenwerkingsgroep voor lymfoomond .. ) kiest REVLIMID voor onderzoek naar tweede meest
[ Wed, Dec 14th 2011 ] - Market Wire
International Drug & Explosives Detection Company IDenta Corp. Reports Sales
[ Wed, Dec 14th 2011 ] - Market Wire
MSA Fire Service Business Gets Boost From Breathing Apparatus Contracts in U.S., Canada and Chile
[ Wed, Dec 14th 2011 ] - Market Wire
Lilly Recognized as One of the Best Places to Work for LGBT Equality
[ Wed, Dec 14th 2011 ] - Market Wire
Amica Mature Lifestyles Announces Closing of Subs .. cluding Exercise in Full of Over-Allotment Option
[ Wed, Dec 14th 2011 ] - Market Wire
Amgen Announces Final Results of Its Tender Offer
[ Wed, Dec 14th 2011 ] - Market Wire
Tortoise Pipeline & Energy Fund Announces Full Investment and Top Ten Holdings
[ Wed, Dec 14th 2011 ] - Market Wire
Pfizer, Cisco, Walt Disney, Research In Motion, U .. ban Outfitters and Green Mountain Coffee Roasters
[ Wed, Dec 14th 2011 ] - Market Wire
A Change in Tides - Featured Research on Keryx Biopharmaceuticals and AEterna Zentaris Inc. (USA)
[ Wed, Dec 14th 2011 ] - Market Wire
St. Jude Medical annuncia il primo impianto nella .. clinica per la valutazione dalla valvola cardiac
[ Wed, Dec 14th 2011 ] - Market Wire
IntegraMed America Selects Adaptive Planning
[ Wed, Dec 14th 2011 ] - Market Wire
CytoSorbents Awarded US Army SBIR Trauma Grant
[ Wed, Dec 14th 2011 ] - Market Wire
Datos finales de la Fase II que evalan REVLIMID y .. eucemia linfoctica crnica recurrente o resistente
[ Wed, Dec 14th 2011 ] - Market Wire
Definitieve fase 2 gegevens van evaluatie REVLIMI .. et recidiverende of refractaire chronische lymfat
[ Wed, Dec 14th 2011 ] - Market Wire
Premiere Cooperative Group in Adult Lymphoma Rese .. for Study in Second Most Common Lymphoma Subtype
[ Wed, Dec 14th 2011 ] - Market Wire
Salix Pharmaceuticals Announces NDA Submission fo .. emer for the Treatment of HIV-Associated Diarrhea
[ Wed, Dec 14th 2011 ] - Market Wire
Meta-analysis of Five Clinical Trials including C .. T Study Published in American Journal of Obstetri
[ Wed, Dec 14th 2011 ] - Market Wire
REVLIMID evaluado en combinacin con rituximab com .. pacientes con leucemia linfoctica crnica no trata
[ Wed, Dec 14th 2011 ] - Market Wire
Presentados en ASH los datos de un estudio de Fas .. en pacientes con mieloma indolente de alto riesgo
[ Wed, Dec 14th 2011 ] - Market Wire
OncoSec Medical Engages The Investor Relations Group
[ Wed, Dec 14th 2011 ] - Market Wire
Rsultats dfinitifs de laessai de phase II valuant .. ez les patients atteints de leucmie lymphocytaire
[ Wed, Dec 14th 2011 ] - Market Wire
Threshold Pharmaceuticals Announces Promising Pha .. Trial Results in Patients With Advanced Leukemias
[ Wed, Dec 14th 2011 ] - Market Wire
REVLIMID a t valu en combinaison avec le Rituxima .. ntiel destin aux patients atteints de leucmie lym
Tue, December 13, 2011
[ Tue, Dec 13th 2011 ] - Market Wire
Abschlieende Phase-II-Daten zur Evaluierung von R .. ienten mit rezidivierter oder refraktrer chronisc
[ Tue, Dec 13th 2011 ] - Market Wire
Risultati finali della fase II analizzano l'effet .. pazienti con leucemia linfocitica cronica refrat

Risultati finali della fase II analizzano l'effetto di REVLIMID e Rituximab in pazienti con leucemia linfocitica cronica refrat


Published on 2011-12-13 19:21:30 - Market Wire
  Print publication without navigation


BOUDRY, Svizzera--([ ])--Celgene International Srl, societ controllata da Celgene Corporation, (NASDAQ: CELG), ha annunciato i risultati finali della fase II di una sua indagine di laboratorio atta a valutare l'efficacia della somministarzione di REVLIMID(lenalidomide) e rituximab in 59 pazienti affetti da leucemia linfocitica refrattaria (LLC) o da ricaduta nello stesso male. Tali dati sono stati presentati alla 53esima conferenza dell'American Society of Hematology tenutasi a San Diego, California.

Il testo originale del presente annuncio, redatto nella lingua di partenza, la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodit del lettore e devono rinviare al testo in lingua originale, che l'unico giuridicamente valido.

Contributing Sources